Compare First Citizens BancShares Inc (FCNCA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Tango Therapeutics Inc. — how do they compare? First Citizens BancShares Inc trades at $2,052.8 (market cap $23.01B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: First Citizens BancShares Inc is far larger — about 6.1× Tango Therapeutics Inc.'s market cap, and First Citizens BancShares Inc pays a 0.4% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 30 Days and Tango Therapeutics Inc. for 0 Days on average.
| FCNCA | TNGX | |
|---|---|---|
Market Cap | $23.01B | $3.75B |
Volume | 64,069 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $32.90 |
52-Week Low | $1.64K | $7.50 |
Typical Hold Time | 30 Days | 0 Days |
Dividend Yield | 0.4% | — |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCNCA trades at $2,075.12, down 0.35% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $57.09 per share, beating estimates, and maintains a net income margin of 25.23%. Recent news includes a $157 million financing deal and branch expansion initiatives, signaling growth. Cash flow improved to a net positive $630 million in 2026 from a slight deficit in 2025.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but technical bearishness and high institutional hold ratings suggest near-term caution. Key risks include execution of expansion and interest rate sensitivity. The stock offers value with a P/E of 11.13, yet requires monitoring of technical levels for entry.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
